Introduction
1. Abbreviations used in this paper: AOSMC, human aortic smooth muscle cells; bFGF, basic fibroblast growth factor; Bn,, maximum binding capacity; [Ca2+ ji, intracellular Ca2+ concentration; cPLA2, cytosolic phospholipase A2; ET, endothelin; ETA, endothelinA receptor; G protein, guanyl nucleotide-binding regulatory protein; HBS, Hepesbuffered saline; IBMX, 3-isobuthyl-l-methylxanthine; Iso, isoprolenaline; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; MIT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PLA2; phospholipase A2; PLC, phospholipase C; SMC, smooth muscle cells.
The endothelin (ET)' family of peptides includes three isoforms termed ET-1, ET-2, and ET-3 ( 1 ) . Since the isolation of ET-1 as a vasoactive peptide released from endothelial cells (2) , effects of ETs on vascular bed have been well characterized. It is now generally agreed that ETs induce vascular constriction through ETA subtype of receptors (ETA) on smooth muscle cells (SMC) (3, 4) and transient relaxation through ETB subtype of receptors (ETB) on vascular endothelium (5) by stimulating the release of endothelium-derived relaxation factor (6, 7) . In addition to their action on vascular tonus, numerous studies described diverse biological activities of the peptides including an action of ETs as a potent mitogen on SMC (8) (9) (10) . Soon after immunoassay systems were established, clinical studies revealed elevated plasma levels of immunoreactive ET in patients with disease conditions such as atherosclerosis (11) or hyperlipoproteinemia (12) and a study on experimental animals described the effect of hypercholesterolemia (13) . These studies suggested the potential significance of mitogenic actions of ETs on SMC during atherogenesis. The involvement of ETs in atherogenesis has been further suggested by studies on cultured cells demonstrating that oxidized low-density lipoproteins, which accumulate in vessel walls during atherogenesis, stimulated macrophages to secrete immunoreactive ET (14) and also endothelial cells to induce expression of mRNA for preproendothelin and release of immunoreactive ET (15) .
According to the current view of atherogenesis ( 16) , atherosclerosis is supposed to be a consequence of an excessive inflammatory-fibroproliferative response of the vascular wall to numerous different forms of stimuli resulting in an accumulation of various kinds of cells including SMC, endothelial cells, and macrophages at the lesion. These cells release various cytokines, growth factors, and vasoactive peptides to influence the phenotype and behavior of neighboring cells. In search of possible targets of therapeutic intervention to halt or reverse atherogenesis, elucidation of the complex interactions of these factors has been a subject of intensive investigation. Previous studies have shown that the transition of the phenotype of SMC from a contractile, nondividing phenotype to a synthetic, dividing phenotype is a critical event in atherogenesis and that, of the various cytokines involved in the process, IL-1, TNF, and TGF secreted by endothelial cells or macrophages play key roles in the phenotype transition (16) .
Because we could confirm the activity of ET-1 as a potent mitogen on cultured SMC from human aorta (AOSMC), as Cell culture and cytokine treatment. Primary-cultured AOSMC were obtained from KURABO (Osaka, Japan). Purity of AOSMC (>95%) was confirmed by immunofluorescence analysis with a mAb against csmooth muscle actin. Cells were routinely maintained at 370C in a C02 incubator (5% C02, 95% air) with DME supplemented with FCS (5%), EGF (10 ng/ml), bFGF (2 ng/ml), and dexamethasone (0.39 jig/ml).
For treatment of the cells with cytokines, cells at -50% confluence in culture wells were made quiescent by incubation for 24 h with serumfree DME and then incubated for 1-24 h (usually for 8 h) in serumfree DME containing an appropriate agent. All experiments were carried out with subcultured cells between the fifth and sixth passages.
Cell proliferation assay. Cells were cultured on 96-well culture plates to -50% confluence. Starved and then cytokine-treated or -untreated cells were further incubated for 48 h in serum-free DME containing ET-1 or other growth factors at the indicated concentrations. The number of viable cells in each well was estimated by the measurement of the rate of mitochondrial metabolism of MTT using a cell proliferation assay kit (Promega Corp.) according to the manufacturer's instructions.
[3HJThymidine incorporation. Cells were cultured on 96-well culture plate to -50% confluence. Starved and then cytokine-treated or -untreated cells were further incubated for 24 h in serum-free DME containing ET-1 or other growth factors at the indicated concentrations.
The cells were exposed to [3H]thymidine (1 ACi/ml) during the last 4 h of the incubation, washed twice with ice-cold PBS, and then incubated with 10% (vol/vol) TCA at 4°C for 30 min. After removing the TCAsoluble material with ethanol, the radioactivity incorporated into the TCA-insoluble fraction was recovered in 0.5 N NaOH and counted with a liquid scintillation counter.
MAPK assays. Cells were grown to -50% confluence in 6-well plates, deprived of serum for 24 h, and then treated or untreated with cytokines. They were washed with PBS and then incubated in serumfree DME supplemented with 5 mM Hepes (pH 7.4). The reaction was started by addition of ET-1 or other stimulants and was terminated by aspiration of the medium and addition of 3 ml of ice-cold lysis buffer (20 mM Tris-HCl, pH 7.4, 80 mM ,B-glycerophosphate, 2 mM DTT, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 10 mM NaF, 1 mM PMSF, 10 lsg/ml leupeptin, and 10 jg/ml aprotinin). The reaction time was 3 min. The cells were collected by scraping the dishes with a rubber policeman, lysed by a brief sonication, and then incubated on ice for 30 min. Insoluble material was removed by centrifugation at 10,000 g for 15 min. MAPKs were partially purified from the lysate by anion exchange chromatography according to the procedures described by Koide et al. (17) . In brief, the lysate was applied to a DEAEcellulose column (0.9 x 0.5 cm) preequilibrated with the lysis buffer. After washing the column with 5 ml of lysis buffer containing 0.1 M NaCl, MAPKs were eluted with 1.0 ml of lysis buffer containing 0.5 M NaCl. Analysis by SDS-PAGE, Western transfer, and immunoblotting with anti-MAPK mAb (Zymed Laboratories, Inc.) verified complete recovery of MAPKs (42-and 44-kD species) in the 0.5 M NaCl eluate (data not shown). The protein concentration of the partially purified lysate was determined with BCA microprotein assay kit, and the lysate was frozen at -800C until assay. Two assay procedures were adopted in this study to measure the MAPK activity in the cell lysate. First, the kinase activity was determined using an assay kit (Amersham International) according to the manufacturer's instructions. In brief, 15 m1 of the cell lysate (2 ug of protein) was added to the same volume of a reaction mixture containing [y-32P]ATP (1 ACi/reaction) and a synthetic peptide (NH2-KRELVEPLTPAGEAPNQALLR-COOH) as a substrate. The reaction was let go at 300C for 30 min and was terminated by adding a stop solution. The resulting solution was applied to a phosphocellulose membrane, and the membrane was extensively washed in 1% acetic acid and then in water. The radioactivity trapped on the membrane was measured with a liquid scintillation counter. Second, the kinase activity was measured by in-gel kinase assay using myelin basic protein (MBP) as a substrate as described by Koide et al. (17) . In brief, cell lysates (5 ug of protein) were resolved by SDS-PAGE on a 12% polyacrylamide gel containing 1 mg/ml of MBP. The gel was washed with buffer A (50 mM Hepes, pH 7.4, containing 5 mM 2-mercaptoethanol) plus 20% of isopropanol at room temperature for 30 min. After denaturation in buffer A containing 6 N guanidine-HCl at room temperature for 1 h and subsequent renaturation in buffer A with 0.04% Tween 40 at 4°C for 16 h, the gel was incubated at 25°C for 1 h in 10 ml of a reaction mixture (25 mM Hepes, pH 7.4, 10 mM MgCl2, 1 mM EGTA, 5 mM 2-mercaptoethanol, 50 /iM ATP, and 250 sCi [y-32P]ATP).
The gel was extensively washed with 5% TCA containing 10 mM pyrophosphate, and the bands of phosphorylated MBP were visualized by BAS2000 (Fujitsu, Tokyo, Japan).
Binding assays. Cells at -50% confluence in 24-well plates were subjected to the assays. After serum-deprivation and plus and minus cytokine treatment, the cells were washed with Hepes-buffered saline (HBS) (20 mM Hepes, pH 7.4, 140 mM NaCl, 4 mM KCl, 1 mM K2HPO4, 1 mM MgCl2, 1 mM CaCl2, 10 mM D-glucose, and 0.1% BSA) and then incubated at 37°C for 1 h in 0.25 ml of HBS containing ['2I]ET-1 to obtain total binding. The concentrations of ['"I]ET-1 used were given in legends. Nonspecific binding was determined in the presence of 100 nM unlabeled ET-1. Specific binding was defined as total binding minus nonspecific binding. The reaction was stopped by aspiration of the reaction buffer, and the cells were washed twice with ice-cold HBS and solubilized in 1 N NaOH. The cell-associated radioactivity was measured in a y-counter.
Measurement of cyclic AMPformation. Cell& at -50% confluence in 24-well plates were starved and then treated or untreated with cytokines. They were washed twice with HBS and then incubated at 370C for 10 min in 1 ml of HBS with or without 1 mM 3-isobuthyl-lmethylxanthine (IBMX). The cells were then stimulated with ET-1 or isoplenaline (Iso) at the concentrations indicated, usually for 3 min. The reaction was stopped by addition of 10% (vol/vol) TCA, and the cAMP contents in the TCA-soluble cell extracts were measured using a radioimmunoassay kit (Amersham International).
Measurement of intracellular Ca"2 concentration ([Ca2+J). Cells in 100-mm culture dishes were dispersed by incubation in PBS containing 1 mM EGTA and loaded with Fura-2 by incubation at 200C for 35 min in HBS containing 4 gM Fura-2/AM. The Fura-2-loaded cells were washed twice, resuspended in HBS, and kept at 200C. Approximately 106 cells/ml were used in each set of experiments. The fluorescence of Fura-2-loaded cells was measured with a CAF-100 spectrofluorometer (Japan Spectroscopy Inc., Tokyo, Japan) with excitations at 340 nm and 380 nm and emission at 500 nm. The [Ca2+]i was calculated from the ratio of fluorescence intensities as described (18) .
Statistical analysis. Results of the experiments were expressed as means±SEM. Student's t test was used for the statistical analysis of the results. P values of < 0.05 were considered to be significant. Results ET-J failed to exert mitogenic activities on IL-1,-treated AOSMC. When applied to quiescent AOSMC, ET-1 induced an increase in mitochondrial metabolism of the dye MTT (Fig. 1) . Because time-course analysis on the effect of ET-1 showed that the maximum increase was obtained after 48 h of exposure (data not shown), the stimulation time was set to 48 h in the subsequent experiments. This increase in MTT metabolism was not simply due to an increased cell viability but, apparently, due to an increase in cell number as revealed by microscopic observation of the culture bed (not shown). The concentration of ET-l to give a half maximum effect (EC50) was within the range of 50-200 pM and the maximum effect obtained at 10 nM ET-1 was -40% of the potency of 5% FCS. AOSMC predominantly expressed ETA subtype of ET receptors as revealed by ['"I]ET-1 binding assays (see below) and the growth-promoting activity of ET-1 was apparently transmitted by ETA; an ETA-selective antagonist BQ123 (3 ,tM) (19) completely suppressed the ET-1 (10 nM) -induced cell proliferation while an ETB-selective antagonist BQ788 (20) (Fig. 1 a) . This effect of IL-1 3 was dependent both on the duration of the treatment and the dose of IL-1p3; the activity of ET-1 to induce cell proliferation was lost after [8] [9] [10] [11] [12] [13] [14] [15] [16] h of exposure to IL-1,f (0.2 ng/ml) and was restored after 24 h of exposure ( Fig. 1 b) , and the concentration higher than 0.1 ng/ml was required to completely suppress the cells' responsiveness ( Fig. 1 c) . Treatments of the cells with any of the other three cytokines caused no changes in the cells' responsiveness to ET-1 (Table I) (Fig. 2 a) (Fig. 2 b) . Of the two isoforms, the 42-kD MAPK was apparently the predominant form on the immunoblot, and in-gel kinase assays revealed that the ET-1-induced increase in the kinase activity was largely attributed to the activation of the 42-kD MAPK. As shown in Fig. 2 (Fig.   3 a) . This increase in the binding was not due to a change in the binding affinities but due to an increase in the maximum (Fig. 4 a) (Fig. 4 b) . ET-I stimulated cAMP formation in IL-I1f-treated AOSMC. It has been reported that, in some cell types, treatment of the cells with IL-1 resulted in an increased expression of phospholipase A2 (PLA2) (28) (29) (30) , which is a rate-limiting enzyme in prostanoids metabolism. An increased production of prostaglandins, via acting in an autocrine/paracrine fashion, might affect the intracellular level of cAMP which works as a negative modulator of MAPK activation cascade (31) (32) (33) . Therefore, we tested the hypothesis that the failure of ET-1 to induce MAPK activation in IL-1f/-treated AOSMC was due to a concomitant increase in cAMP formation secondary to activated prostanoids metabolism.
ET-1 did not stimulate cAMP formation in IL-1/3-untreated AOSMC, whereas a fl-adrenergic receptor agonist Iso significantly increased the cAMP content (Fig. 5 a) . When the cells were treated with IL-1p (0.2 ng/ml) for 4 h, however, ET-1 caused a significant increase in cAMP formation. Peak level of ET-1 -induced cAMP increase was obtained within 4-8 h of IL-13P treatment, and the ability of ET-1 to stimulate cAMP formation declined gradually and disappeared after 24 h of treatment (Fig. 5 a) . The effect of ET-1 on IL-(l,-treated cells (0.2 ng/ml for 8 h) was dose dependent with EC50 values of -300 pM and the maximum effects of three-to fourfold increase above the basal levels (Fig. 5 b) . IL-1,B treatment caused no significant changes either in basal or Iso-stimulated cAMP formations. The ET-l-induced cAMP increase was not observed in cells incubated for 8 h with IL-8 (10 ng/ml), TNFa (5 ng/ml), or TGFP (5 ng/ml) (data not shown).
BQ123 completely suppressed the ET-1 -induced cAMP increase in 1L-1/3-treated AOSMC ( (Table Ill) . Second, a PLC inhibitor, U-73122, at 10 IM (the concentration high enough to suppress ET-l [10 nM] -induced [Ca2"]i response in AOSMC; Ninomiya, H., unpublished observations), also blocked the effect of ET-1 (Table III) . Neither indomethacin nor U-73122 inhibited Iso-induced cAMP formation. Third, not only ET-1 but other Ca2 -mobilizing agents such as angiotensin H or ionomycin stimulated cAMP formation in IL-If3-treated cells (Table IV) (Table  V) , which presumably was required for the increased expressions of enzymes involved in prostanoids metabolism. Indomethacin restored the ET-J-induced mitogenic responses ofIL-1/3-treatedAOSMC. According to the hypothesis that an increase in cAMP formation secondary to ET-1 -induced prostanoids production impaired the mitogenic responses of IL-1I3-treated cells, suppression of prostanoids metabolism should restore the responses. Indeed, when IL-Ifi-treated cells were incubated with indomethacin (10 AtM) before stimulation, ET-1 caused significant increases both in MAPK activity at 3 min and in [3H]thymidine incorporation after 24 h (Fig. 6 ). (Fig. 6 ). These results indicated that the molecular apparatus to transmit the mitogenic activities of ET-l remained intact in IL-/l3-treated AOSMC and gave confirmatory evidence for the hypothesis described above.
Discussion
In the case of SMC, initial studies demonstrating mitogenic effects of ETs (8) (9) (10) were followed by contradictory reports (38) . Although these conflicting findings may simply reflect differences between the types of cells and the various experimental protocols used in each laboratory, the precise reason(s) for the discrepancies is unknown. In this study, we showed that, when applied to quiescent AOSMC, ET-1 alone, without any other growth-promoting agent, could induce MAPK activation, DNA synthesis, and cell proliferation. The observed effect of ET-1 on the cell proliferation, which is the end-point result of mitogenic activities, was as potent as about half of that of 5% FCS (Fig. 1) . These results firmly confirmed the mitogenic activities of ET-1 on AOSMC. We also demonstrated that, when cells were treated with ILl1/, a concomitant increase in cAMP formation secondary to ET-l -induced prostanoids production dramatically changed the mitogenic responses of the cells. Because in some types of SMC ET-1 has been reported to stimulate cAMP formation without any drug treatment (39) , one of the reasons for the conflicting results obtained in the previous studies could be the differences of the effects of ET-1 on cAMP formation between types (and states) of the cells. cAMP-increasing agents such as adenosine or prostaglandin E have been known to counteract the mitogenic actions of various growth factors on SMC (40, 41) , and accumulating evidence suggested that cAMP/cAMP-dependent kinase signaling inhibits the upstream of MAPKs in the signal transduction pathways activated by growth factor receptors. cAMP-increasing agents such as IBMX, forskolin, or prostaglandin E have been shown to inhibit Ras-dependent activation of Raf-l, B-raf, or MAPK kinase kinase stimulated by EGF, nerve growth factor, or a phorbol ester (31) (32) (33) . The failure of ET-1 to induce MAPK activation in IL-1,f-treated AOSMC (Fig. 2) with a concomitant increase in cAMP formation (Fig. 5) is in accordance with these previous findings. Because the increase in cAMP formation in IL-ifI/-treated AOSMC was apparently secondary to prostanoids production stimulated by an ET-1-induced increase in [Ca2+]i (Tables III and IV In addition to the induction of enzymes involved in prostanoids metabolism, IL-pI has been reported to stimulate proliferation of SMC via induction of PDGF-A-chain gene (47) (Fig. 3) . This increase was not accompanied by any enhancement of the ET-l-induced signaling (Fig.  4) , and its significance on the ET-1-induced cell responses remains unknown. As for the molecular mechanism of the upregulation, a preliminary study with Northern blotting analysis using human ETA cDNA as a probe failed to reveal any significant changes in the expressions of ETA mRNA caused by IL-,1( treatment (data not shown), suggesting an influence of IL-1/3 on the translational control or on the stability of the receptor protein.
Regardless of the molecular mechanisms involved, the findings described in this study gave a new insight into the possible role of ETs under inflammatory conditions during atherogenesis. IL-1,8 is a major cytokine released from activated macrophages which accumulate in the atherotic lesions and acts as a multipotent inflammatory mediator (16, 47) . Various lines of evidence suggested that the conditions predisposed to atherogenesis or factors involved in it caused elevated plasma or tissue levels of ETs (11) (12) (13) (14) (15) 
